155 related articles for article (PubMed ID: 9767230)
1. Fas ligand is expressed in normal skin and in some cutaneous malignancies.
Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Shin MS; Dong SM; Na EY; Kim KM; Kim CS; Kim SH; Yoo NJ
Br J Dermatol; 1998 Aug; 139(2):186-91. PubMed ID: 9767230
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of Fas and FasL pro-apoptotic proteins in basal cell and squamous cell carcinomas.
Wang XY; Zhang R; Lian S
Clin Exp Dermatol; 2011 Jan; 36(1):69-76. PubMed ID: 20497185
[TBL] [Abstract][Full Text] [Related]
3. Transitional cell carcinoma expresses high levels of Fas ligand in vivo.
Lee SH; Lee JY; Park WS; Kim SY; Jang JJ; Yoo NJ
BJU Int; 1999 Apr; 83(6):698-702. PubMed ID: 10233582
[TBL] [Abstract][Full Text] [Related]
4. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
5. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.
Zoi-Toli O; Vermeer MH; De Vries E; Van Beek P; Meijer CJ; Willemze R
Br J Dermatol; 2000 Aug; 143(2):313-9. PubMed ID: 10951138
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD40 and Fas ligand in Bowen's disease, squamous cell carcinoma and basal cell carcinoma.
Jang TJ
Yonsei Med J; 2002 Jun; 43(3):304-8. PubMed ID: 12089736
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand downregulation with antisense oligonucleotides in cells and in cultured tissues of normal skin epidermis and basal cell carcinoma.
Ji J; Wernli M; Buechner S; Erb P
J Invest Dermatol; 2003 Jun; 120(6):1094-9. PubMed ID: 12787140
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of Fas ligand expression in normal human tissues.
Lee SH; Shin MS; Park WS; Kim SY; Dong SM; Lee HK; Park JY; Oh RR; Jang JJ; Lee JY; Yoo NJ
APMIS; 1999 Nov; 107(11):1013-9. PubMed ID: 10598873
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis in different cutaneous manifestations of lupus erythematosus.
Baima B; Sticherling M
Br J Dermatol; 2001 May; 144(5):958-66. PubMed ID: 11359381
[TBL] [Abstract][Full Text] [Related]
11. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
12. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
13. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines.
Oishi M; Maeda K; Sugiyama S
Arch Dermatol Res; 1994; 286(7):396-407. PubMed ID: 7529480
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
15. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of Fas on human epidermal cells after in vivo exposure to single-dose ultraviolet (UV) B or long-wave UVA radiation.
Bang B; Rygaard J; Baadsgaard O; Skov L
Br J Dermatol; 2002 Dec; 147(6):1199-206. PubMed ID: 12452871
[TBL] [Abstract][Full Text] [Related]
18. Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis.
Rigberg DA; Centeno J; Kim FS; Ke B; Swenson K; Maggard M; McFadden DW
J Surg Oncol; 1999 Jun; 71(2):91-6. PubMed ID: 10389864
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury.
Nakajima M; Nakajima A; Kayagaki N; Honda M; Yagita H; Okumura K
Clin Immunol Immunopathol; 1997 Jun; 83(3):223-9. PubMed ID: 9175910
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cell death in NR-S1 tumor by photodynamic therapy: possible involvement of Fas and Fas ligand system.
Yokota T; Ikeda H; Inokuchi T; Sano K; Koji T
Lasers Surg Med; 2000; 26(5):449-60. PubMed ID: 10861700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
